At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Market Closed 05-15 16:00:00 EDT
0.6705
-0.0321
-4.57%
盘后0.6885
+0.0180+2.68%
19:50 EDT
High0.7000Low0.6501Vol877.96K
Open0.6849D1 Closing0.7026Amplitude7.10%
Mkt Cap20.88MTradable Cap17.97MTotal Shares31.15M
T/O596.07KT/O Rate3.28%Tradable Shares26.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Benzinga  ·  05-14
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Longeveron Q1 revenue rises, beats analyst estimates
Reuters  ·  05-14
Longeveron Q1 revenue rises, beats analyst estimates
BRIEF-Longeveron Q1 EPS USD -0.19
Reuters  ·  05-14
BRIEF-Longeveron Q1 EPS USD -0.19
Longeveron Q1 Revenue USD 378 Thousand
THOMSON REUTERS  ·  05-14
Longeveron Q1 Revenue USD 378 Thousand
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
GlobeNewswire  ·  05-14
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000
Reuters  ·  05-14
Longeveron Q1 net loss narrows 6% to $4.74 million; revenue rises to $398,000
Longeveron reports DMC approval for laromestrocel study to continue as designed
TIPRANKS  ·  05-12
Longeveron reports DMC approval for laromestrocel study to continue as designed
Longeveron Cut to Hold From Buy by Maxim Group
Dow Jones  ·  05-12
Longeveron Cut to Hold From Buy by Maxim Group
Longeveron downgraded to Hold from Buy at Maxim
TIPRANKS  ·  05-11
Longeveron downgraded to Hold from Buy at Maxim
Longeveron DMC clears Phase 2b HLHS stem cell trial to complete
Reuters  ·  05-11
Longeveron DMC clears Phase 2b HLHS stem cell trial to complete
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)
THOMSON REUTERS  ·  05-11
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)
Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026
THOMSON REUTERS  ·  05-11
Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026
Longeveron Inc - DMC Finds No Safety Concerns, Recommends Phase 2B Trial Continue to Completion
THOMSON REUTERS  ·  05-11
Longeveron Inc - DMC Finds No Safety Concerns, Recommends Phase 2B Trial Continue to Completion
Longeveron provides update on laromestrocel development after Type C meeting
TIPRANKS  ·  05-09
Longeveron provides update on laromestrocel development after Type C meeting
Longeveron Updates FDA Path for ELPIS II Trial
TIPRANKS  ·  05-09
Longeveron Updates FDA Path for ELPIS II Trial
Longeveron Says the FDA No Longer Sees Trial for Heart Syndrome Treatment as Pivotal
Dow Jones  ·  05-09
Longeveron Says the FDA No Longer Sees Trial for Heart Syndrome Treatment as Pivotal
Longeveron targets August ELPIS II Phase 2b HLHS data readout for laromestrocel
Reuters  ·  05-09
Longeveron targets August ELPIS II Phase 2b HLHS data readout for laromestrocel
Longeveron Inc - FDA Says New Primary Endpoint for Elpis Ii Cannot Be Agreed While Trial Ongoing
THOMSON REUTERS  ·  05-09
Longeveron Inc - FDA Says New Primary Endpoint for Elpis Ii Cannot Be Agreed While Trial Ongoing
Longeveron Announces Constructive Type C Meeting With U.S. FDA Ahead of Data Readout for Elpis Ii Phase 2B Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
THOMSON REUTERS  ·  05-09
Longeveron Announces Constructive Type C Meeting With U.S. FDA Ahead of Data Readout for Elpis Ii Phase 2B Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
GlobeNewswire  ·  05-06
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--